Novo Nordisk Acquires UBT251 Drug

This is a news story, published by CNBC, that relates primarily to Novo Nordisk news.

Novo Nordisk news

For more Novo Nordisk news, you can click here:

more Novo Nordisk news

drug discoveries news

For more drug discoveries news, you can click here:

more drug discoveries news

CNBC news

For more news from CNBC, you can click here:

more news from CNBC

About the Otherweb

Otherweb, Inc is a public benefit corporation, dedicated to improving the quality of news people consume. We are non-partisan, junk-free, and ad-free. We use artificial intelligence (AI) to remove junk from your news feed, and allow you to select the best health news, business news, entertainment news, and much more. If you like drug discoveries news, you might also like this article about

other pharmaceutical giants

. We are dedicated to bringing you the highest-quality news, junk-free and ad-free, about your favorite topics. Please come every day to read the latest Chinese pharmaceutical company United Laboratories International news, obesity drugs news, drug discoveries news, and other high-quality news about any topic that interests you. We are working hard to create the best news aggregator on the web, and to put you in control of your news feed - whether you choose to read the latest news through our website, our news app, or our daily newsletter - all free!

Chinese biotech companies

CNBC

•

Health

Healthy Returns: Novo Nordisk scoops up Chinese obesity drug to compete with Eli Lilly

Summary

Nutrition label

84% Informative

Danish drugmaker Novo Nordisk has agreed to pay $2 billion for rights to an experimental drug.

UBT251 is in early development to treat obesity, Type 2 diabetes and other conditions.

It takes a three -pronged approach to promoting weight loss and regulating blood sugar.

The Danish drug company joins a slate of other pharmaceutical giants that have recently inked relatively cheap deals with Chinese biotech companies for obesity drugs.

The number of doctors who thought about leaving the profession declined 22% from last year .

Only 27% of physicians believe AI is overhyped, compared to 40% of last year's survey.

Only 6% of respondents use Athenahealth 's electronic health record software.

Doctors are concerned about demanding regulatory requirements and the lack of data-sharing between systems.

VR Score

Informative language

Neutral language

Article tone

semi-formal

Language

English

Language complexity